171 related articles for article (PubMed ID: 24390216)
1. Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors.
Larson AR; Dresser KA; Zhan Q; Lezcano C; Woda BA; Yosufi B; Thompson JF; Scolyer RA; Mihm MC; Shi YG; Murphy GF; Lian CG
Mod Pathol; 2014 Jul; 27(7):936-44. PubMed ID: 24390216
[TBL] [Abstract][Full Text] [Related]
2. 5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma.
Pavlova O; Fraitag S; Hohl D
J Invest Dermatol; 2016 Dec; 136(12):2453-2461. PubMed ID: 27456754
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
[TBL] [Abstract][Full Text] [Related]
4. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
Skender-Kalnenas TM; English DR; Heenan PJ
J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
[TBL] [Abstract][Full Text] [Related]
5. Melanocytic nevi and tumor progression: perspectives concerning histomorphology, melanoma risk and molecular genetics.
Barnhill RL
Dermatology; 1993; 187(2):86-90. PubMed ID: 8358111
[TBL] [Abstract][Full Text] [Related]
6. 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms.
Lee JJ; Vilain RE; Granter SR; Hu NR; Bresler SC; Xu S; Frank AH; Mihm MC; Saw RP; Fletcher CD; Scolyer RA; Murphy GF; Lian CG
J Cutan Pathol; 2017 Mar; 44(3):249-255. PubMed ID: 28032662
[TBL] [Abstract][Full Text] [Related]
7. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia.
Clark WH; Hood AF; Tucker MA; Jampel RM
Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124
[TBL] [Abstract][Full Text] [Related]
8. 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies.
Lee JJ; Granter SR; Laga AC; Saavedra AP; Zhan Q; Guo W; Xu S; Murphy GF; Lian CG
Mod Pathol; 2015 Feb; 28(2):218-29. PubMed ID: 25081754
[TBL] [Abstract][Full Text] [Related]
9. BRAF and NRAS mutations in spitzoid melanocytic lesions.
Fullen DR; Poynter JN; Lowe L; Su LD; Elder JT; Nair RP; Johnson TM; Gruber SB
Mod Pathol; 2006 Oct; 19(10):1324-32. PubMed ID: 16799476
[TBL] [Abstract][Full Text] [Related]
10. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
11. Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
Melamed RD; Aydin IT; Rajan GS; Phelps R; Silvers DN; Emmett KJ; Brunner G; Rabadan R; Celebi JT
J Invest Dermatol; 2017 Apr; 137(4):905-909. PubMed ID: 27890785
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
13. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
Piris A; Mihm MC; Hoang MP
Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations.
Rodić N; Zampella J; Sharma R; Burns KH; Taube JM
J Cutan Pathol; 2015 Nov; 42(11):807-14. PubMed ID: 26239102
[TBL] [Abstract][Full Text] [Related]
16. Prediction of histologic melanocytic dysplasia from clinical observation.
Roush GC; Dubin N; Barnhill RL
J Am Acad Dermatol; 1993 Oct; 29(4):555-62. PubMed ID: 8408790
[TBL] [Abstract][Full Text] [Related]
17. 5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi.
Uchiyama R; Uhara H; Uchiyama A; Ogawa E; Takazawa Y; Ashida A; Koga H; Hayashi K; Kiniwa Y; Okuyama R
J Dermatol Sci; 2014 Feb; 73(2):161-3. PubMed ID: 24169492
[No Abstract] [Full Text] [Related]
18. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis.
Kapur P; Selim MA; Roy LC; Yegappan M; Weinberg AG; Hoang MP
Mod Pathol; 2005 Feb; 18(2):197-204. PubMed ID: 15467715
[TBL] [Abstract][Full Text] [Related]
19. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.
Lian CG; Xu Y; Ceol C; Wu F; Larson A; Dresser K; Xu W; Tan L; Hu Y; Zhan Q; Lee CW; Hu D; Lian BQ; Kleffel S; Yang Y; Neiswender J; Khorasani AJ; Fang R; Lezcano C; Duncan LM; Scolyer RA; Thompson JF; Kakavand H; Houvras Y; Zon LI; Mihm MC; Kaiser UB; Schatton T; Woda BA; Murphy GF; Shi YG
Cell; 2012 Sep; 150(6):1135-46. PubMed ID: 22980977
[TBL] [Abstract][Full Text] [Related]
20. Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma.
Gambichler T; Sand M; Skrygan M
Melanoma Res; 2013 Jun; 23(3):218-20. PubMed ID: 23458759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
